MedTrace Logo

Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma

NCT03937843 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2026-01-20

No results posted yet for this study

Summary

The trial investigates a stage-adapted (stage IIA or IIB) de-escalation of the standard treatments in the context of a multimodality treatment with chemo- and radiotherapy in seminoma patients. The goal is to safely de-escalate treatment while maintaining/enhancing efficacy, which is not a standard practice yet.

Conditions

  • Seminoma
  • Testicular Cancer

Interventions

DRUG

Carboplatin

Patients in cohort 1 will receive a 60-minute i.v. infusion of carboplatin AUC 7 at day 1 of treatment.

DRUG

Cisplatin

Patients in cohort 2 will receive on day 1 to day 5: * a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by * a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day.

DRUG

Etoposide

Patients in cohort 2 will receive on day 1 to day 5: * a 60-minutes i.v. infusion of etoposide 100mg/m2 per day followed by * a 60-120 minutes i.v. infusion of cisplatin 20mg/m2 per day.

Sponsors & Collaborators

  • German Testicular Cancer Study Group

    collaborator OTHER

  • Swiss Cancer Institute

    lead OTHER

Principal Investigators

  • Alexandros Papachristofilou, MD · Universitätsspital Basel

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-29
Primary Completion
2026-12-31
Completion
2046-12-31

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03937843 on ClinicalTrials.gov